Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had cancer antibody treatment or experimental therapy in the last 28 days.My side effects from previous treatments, except for hair loss or stable nerve damage, have mostly gone away.I stopped previous immune therapy due to severe side effects needing steroids.I haven't taken steroids or immunosuppressants in the last 14 days.I have or had lung inflammation caused by a drug.I have been treated with an anti-4-1BB antibody before.I haven't had chemotherapy, radiation, or targeted therapy recently and have recovered from their side effects.My blood, liver, and kidney tests are all within normal ranges.My cancer has returned or didn't respond to treatment and cannot be surgically removed.I have risk factors for bowel issues, like a history of severe gut infections or abdominal cancer spread.
- Group 1: ABL503
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have been accepted into this scientific experiment?
"To complete the research at hand, 36 suitable candidates must take part in this experiment. People can sign up through NEXT Oncology, located in San Antonio Texas or Sarah Cannon Research Institute at HealthONE which is found in Denver Colorado."
Is this clinical research endeavor currently recruiting participants?
"Correct. According to clinicaltrials.gov, this medical study began recruiting participants on April 1st 2021 and is presently seeking volunteers for enrollment. The investigation requires 36 individuals from 5 distinct healthcare facilities."
How hazardous is ABL503 for human consumption?
"Since ABL503 is only in its inaugural trial, the safety rating was evaluated as a 1 due to limited evidence of efficacy and security."
Are there any hospitals in North America conducting this research initiative?
"Patients have the option of enrolling in this trial at 5 separate medical facilities: NEXT Oncology, Sarah Cannon Research Institute, City of Hope Duarte and 2 other sites."
Share this study with friends
Copy Link
Messenger